<DOC>
	<DOCNO>NCT03055624</DOCNO>
	<brief_summary>Investigator-initiated study evaluate safety efficacy prostate artery embolization treatment low urinary tract symptom patient benign prostatic hyperplasia</brief_summary>
	<brief_title>Prostate Artery Embolization Treatment Symptomatic Benign Prostatic Hyperplasia</brief_title>
	<detailed_description>This phase I/II , single center , prospective , single arm , investigational study evaluate safety efficacy prostate artery embolization ( PAE ) treatment severe low urinary tract symptom ( LUTS ) relate benign prostatic hyperplasia ( BPH ) patient either fail intolerant medical management . Once eligibility confirm , patient undergo PAE Embosphere Microspheres . Embolization consist minimally invasive angiogram treatment prostate artery Embosphere particles reduce blood flow prostate . Following treatment , patient return follow-up visit 1 , 6 , 12 , 24 month post PAE .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<criteria>1 . Prostate volume 40 300 cm3 2 . Diagnosis BPH moderate severe low urinary tract symptom ( LUTS ) define least one following : a. IPSS great 18 b. IPSS Quality Life ( QoL ) assessment great 3 c. Qmax le 12 mL/sec 3 . Refractory intolerant medical management 4 . Ineligibility refusal surgical management 5 . One follow criterion : a. Baseline prostate specific antigen ( PSA ) ≤2.5 ng/mL b. Baseline PSA &gt; 2.5 ng/mL ≤10 ng/mL AND free PSA ≥25 % total PSA c. Baseline PSA &gt; 2.5 ng/mL ≤10 ng/mL AND free PSA &lt; 25 % total PSA AND negative 12 core prostate biopsy past 12 month d. Baseline PSA &gt; 10 ng/mL AND negative 12 core biopsy within past 12 month . 1 . History prostate , bladder rectal malignancy . Biopsy proven urethral cancer . 2 . History rectal disease 3 . Neurogenic bladder disorder due multiple sclerosis , Parkinson 's disease , spinal cord injury , diabetes , etc. , demonstrate urodynamic testing . 4 . Detrusor muscle failure , urethral stenosis , urinary obstruction due cause BPH , demonstrate urodynamic test 5 . Bladder diverticulum great 5 cm bladder stone great 2 cm 6 . Cystolithiasis within past three month 7 . Baseline serum creatinine great 1.8 8 . Evidence tortuous atherosclerotic blood vessel 9 . Presence collateral vessel pathway potentially endanger normal territory embolization bypass microcatheter 10 . Active urinary tract infection , interstitial cystitis , prostatitis within last 5 year 11 . Coagulation disturbance normalize medical treatment 12 . Allergy iodinate contrast agent responsive steroid premedication regimen 13 . Previous radical pelvic rectal surgery , pelvic irradiation 14 . Prior surgical prostate intervention 15 . Treatment betablocker , antihistamine , anticonvulsant , antispasmodic medication within 1 week treatment UNLESS stable voiding pattern medicate drug ( ) 6 month 16 . Use prostate active medication , include alpha blocker , anticholinergic , androgen , antiandrogens , gonadotropinsreleasing hormonal analog , PDE5inhibitors , 5alpha reductase inhibitor within 2 month intervention , unless medication necessary avoid symptom exacerbation disability , case medication initiate dose adjust within 1 month study enrollment dose adjust study period 17 . Interest future fertility 18 . Mental condition disorder interfere participant ' ability provide write informed consent 19 . Current severe uncontrolled disease ( metabolic , hematologic , renal , hepatic , pulmonary , neurologic , cardiac , infectious gastrointestinal ) Investigator 's judgment make patient unsuitable trial inclusion due increase risk complication 20 . Known immunosuppression 21 . Life expectancy le 6 month</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>prostate artery embolization ( PAE )</keyword>
	<keyword>benign prostatic hyperplasia ( BPH )</keyword>
	<keyword>low urinary tract symptom ( LUTS )</keyword>
</DOC>